Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2025-5500

Published: 2025

Journal Articles

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

Sattva Neelapu, Moshe Fridman, Mark Ray, Sally Wade, Jacob Wulff, David Cobley, Jenny Kim, Julio Chavez

Blood (2025) 146 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2025-3717

Published: 2025

Journal Articles

Targeting B- and T-cell lymphomas with anti-CXCR5 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 3709.

https://doi.org/10.1182/blood-2025-3709

Published: 2025

Journal Articles

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 477.

https://doi.org/10.1182/blood-2025-477

Published: 2025

Journal Articles

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Blood (2025) 146 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2025-5834

Published: 2025

Journal Articles

Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma

Kristyna Kupcova, Nahum Puebla, Aarthi Goverdhan, Adriana Velasova, Bree Lege, Zahid Rafiq, Victoria Roko, Esha Pisipati, Jingwei Liu, Shao-Qing Kuang, Mien-Chie Hung, Sattva Neelapu, Richard Davis, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 435.

https://doi.org/10.1182/blood-2025-435

Published: 2025

Journal Articles

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2025-1931

Published: 2025

Journal Articles

A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies

Blood (2025) 146 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2025-2337

Published: 2025

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

Blood (2025) 146 (Supplement 1): 666.

https://doi.org/10.1182/blood-2025-666

Published: 2025

Journal Articles

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2025-7092

Published: 2025

Journal Articles

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Rahul Shah, Xiaowen Sun, Lei Feng, Anath Lionel, Zachary Hunzeker, Sairah Ahmed, Jeremy Ramdial, Michelly Abreu, Karla Ow, Minifrida Santiago, Jaimole Varghese, Sherry Adkins, Misha Hawkins, Sandra Horowitz, Amy Ayers, Partow Kebriaei, Elizabeth Shpall, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 6319.

https://doi.org/10.1182/blood-2025-6319

Published: 2025

Journal Articles

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Dai Chihara, Paolo Strati, Preetesh Jain, Luis Fayad, Frederick Hagemeister, Maria Rodriguez, Richard Davis, Michael Wang, Sattva Neelapu, Christopher Flowers, Jason Westin

Blood (2025) 146 (Supplement 1): 5369.

https://doi.org/10.1182/blood-2025-5369

Published: 2025

Journal Articles

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

Blood (2025) 146 (Supplement 1): 806.

https://doi.org/10.1182/blood-2025-806

Published: 2025

Journal Articles

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Paolo Strati, Lei Feng, Luis Malpica, Ranjit Nair, Ayushi Chauhan, Dai Chihara, Zachary Hunzeker, Laura Murphy, Elizabeth McChesney, Derek Waters, Jason Westin, Sattva Neelapu, Christopher Flowers

Blood (2025) 146 (Supplement 1): 3571.

https://doi.org/10.1182/blood-2025-3571

Published: 2025

Journal Articles

Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming

Blood (2025) 146 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2025-3326

Published: 2025

Journal Articles

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2025-3691

Published: 2025

Journal Articles

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Rahul Shah, Zhiping Luo, Rhodora Fontillas, Betty Holder, Nicholas Szewczyk, Amy Ayers, Uday Popat, Elizabeth Shpall, Paolo Strati, Chijioke Nze, Preetesh Jain, Michael Wang, Jason Westin, Sattva Neelapu, Amy Ng, Ki Shin, Sairah Ahmed, An Ngo-Huang, Dai Chihara

Blood (2025) 146 (Supplement 1): 2719.

https://doi.org/10.1182/blood-2025-2719

Published: 2025

Journal Articles

Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma

Zachary Hunzeker, Anath Lionel, Xiaowen Sun, Lei Feng, Sairah Ahmed, Amy Ayers, Michelly Abreu, Jaimole Varghese, Karla Ow, Amelita Marzan, Taylor Cain, Minifrida Santiago, Sreekala Nair, Jeremy Ramdial, Elizabeth Shpall, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 2713.

https://doi.org/10.1182/blood-2025-2713

Published: 2025

Journal Articles

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Sameer Melinkeri, Rahul Bhargava, Neeraj Siddarthan, Dr Dinesh Bhurani, Jayachandran P.K., Esha Kaul, Prashant Mehta, Hari Menon, Bhausaheb Bagal, Kunal Goyal, Prakash Shekhawat, Pavan Kumar Boyella, Rakesh Boya, Ram Abhinav, Rayaz Ahmed, Anil Aribandi, Ashwin V Nair, Chandran Nair, Harish Palaparthi, Lingaraj Nayak, Pawan Singh, Priyanshi Pachauri, Rajat Bhattacharya, Rajiv Kumar, Ranjit Sahoo, Sharat Damodar, Vikram Mathews, Vasu Babu Goli, Abhishek Charan, Ajay Gupta, Amul Kapoor, Anupam Chakrapani, Ashish Bakshi, Bijay Prabhakaran Nair, Bilal Kazi, Debranjani Chattopadhyay, Ganesh S. Jaishetwar, Kaushal Kalra, Kishore Kumar, Lekshmon K.S, Madhav Danthala, Mallikarjun Kalashetty, Narendra Anukonda, Naveen Gupta, Nivedita Dhingra, Padmaja Lokireddy, Prasad Narayanan, Parathan Karunakaran, Prasanth Ganesan, Punit Jain, Priyanka Samal, Ramaswamy N.V., Rajan Kapoor, Shyam Aggarwal, Roy J Palatty, Sainath Bhethanabhotla, Sachin Almel, Santhosh Devadas, Sivakumaran Janakiraman, Sudeep V, Sreeraj Vasudevan, Sameer Tulpule, Suraj Chiraniya, Vijay Patil, Sumita Chaudhry, T Raja, Sunu Cyriac, Shishir Seth, Chezhian Subash, Varun Rajan, Alok Shetty, Vishwanath Sathyanarayanan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayashree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2025-6288

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

Targeting B- and T-cell lymphomas with anti-CXCR5 CAR T cell therapy

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only